Search for a command to run...
BACKGROUND: At present, there is a lack of detailed information on the activities of organizations engaged in drug compounding, the state of their infrastructure, and the demand for services related to drug compounding for state and municipal needs. AIM: This work aimed to systematize indicators characterizing the activities of organizations engaged in drug compounding and to determine future directions for the development of drug compounding in the Volga Federal District. METHODS: A sociological study of medical and pharmacy organizations licensed for pharmaceutical activity with authorization to compound medicinal products was conducted using remote questionnaire-based surveys. Data from the Unified Register of Licenses; data from the Unified Register of Licenses for Activities Related to the Circulation of Narcotic Drugs, Psychotropic Substances, and Their Precursors; results of the socioeconomic assessment conducted by the Federal State Statistics Service; and data from the Unified Information System for Procurement were used. The work applied a survey method in the form of remote questionnaires as well as desk research methods. RESULTS: The findings indicate a more than 1.5-fold increase in demand for drug compounding services in the public healthcare sector of the Volga Federal District from 2021 to 2024, reaching 487.16 million rubles. Procurement of drug compounding services for medical use funded by regional budgets was carried out in 8 of the 14 constituent entities of the Volga Federal District, with an annual increase in demand of 40.2%. It was established that at least 127 organizations engaged in drug compounding (by registered addresses of pharmaceutical activity) operate within the district, accounting for 18.6% of the total number in the Russian Federation. Authorization to compound medicinal products from the list of narcotic drugs and psychotropic substances is held by pharmacy organizations operating in 9 of the 14 analyzed constituent entities of the Russian Federation, indicating limited accessibility of personalized pharmacotherapy. In 2023, a total of 6320 medicinal products were compounded, representing approximately 14.0% of the total compounding volume in the Russian Federation. Compounding was performed using at least 128 pharmaceutical substances. During compounding, at least 147 international nonproprietary names of registered medicinal products were used. CONCLUSION: The study identified the main qualitative and quantitative characteristics of organizations engaged in drug compounding in the Volga Federal District and determined the demand within public procurement of services related to drug compounding in the district.